Failed Johnson & Johnson, Pfizer Inc. Alzheimer's Drug Was Hitting Target

Data from two large studies of Pfizer Inc and Johnson & Johnson's Alzheimer's drug, bapineuzumab, show the treatment reduced underlying markers of the disease in some patients, suggesting the failed medication might work at an earlier stage. The findings, presented at a European neurology meeting in Stockholm, followed the companies' announcement last month that they were scrapping large-scale clinical trials of the drug after it failed to improve memory or thinking skills in patients with mild to moderate Alzheimer's.